Clinical Trial Update: Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating serplulimab with chemoradiotherapy for postoperative cervical cancer with risk factors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Serplulimab (serplulimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Cervical Cancers | Phase 2 | Status: RECRUITING